New Frontiers in Dermatology: Oral Therapies for Psoriasis & Melasma

Abstract

Recent advancements in dermatology have introduced novel oral therapies for chronic skin conditions such as psoriasis and melasma, shifting paradigms in systemic management. This review provides a comprehensive analysis of contemporary oral treatments, their mechanisms, clinical efficacy, safety profiles, and relevance to current clinical practice. By synthesizing the latest guideline-based recommendations and emerging scientific evidence, the article aims to inform clinicians about the evolving landscape of oral therapeutics, with emphasis on individualized patient care and practical application.

Introduction

Psoriasis and melasma are prevalent dermatological disorders that pose significant therapeutic challenges due to their chronicity, psychosocial impact, and the limitations of conventional therapies. While topical and phototherapeutic interventions remain foundational, oral therapies have emerged as critical adjuncts and alternatives, especially for patients with moderate-to-severe disease or recalcitrant cases. This review examines the epidemiological context, underlying mechanisms, clinical presentations, diagnostic approaches, and the expanding armamentarium of oral agents for psoriasis and melasma, with a focus on translational relevance for dermatology practitioners.

Epidemiology / Disease Burden

Psoriasis affects approximately 2–3% of the global population, with notable variations by ethnicity and geography. The disease commonly manifests in early adulthood and is associated with substantial morbidity, including comorbid conditions such as psoriatic arthritis, metabolic syndrome, and cardiovascular disease. Melasma, on the other hand, disproportionately affects women of reproductive age, particularly those with Fitzpatrick skin types III–V, and is prevalent in regions with high ultraviolet exposure. Both conditions contribute to impaired quality of life, psychological distress, and economic burden, reinforcing the imperative for effective long-term management strategies.

Pathophysiology

Psoriasis is an immune-mediated disorder driven by dysregulated interplay between keratinocytes, dendritic cells, and T lymphocytes. Central to its pathogenesis are the Th17 and Th1 pathways, with interleukins IL-17, IL-23, and TNF-α playing pivotal roles in perpetuating cutaneous inflammation and epidermal hyperproliferation. Melasma is characterized by epidermal and dermal hypermelanosis, influenced by ultraviolet radiation, hormonal fluctuations (e.g., estrogen, progesterone), and genetic predisposition. Recent insights implicate the role of cutaneous inflammation, vascular factors, and oxidative stress in melasma, expanding the therapeutic targets beyond melanogenesis inhibition.

Risk Factors

Risk factors for psoriasis include genetic susceptibility (notably HLA-Cw6 alleles), family history, obesity, smoking, infections (streptococcal pharyngitis), and certain medications (e.g., beta-blockers, lithium). Melasma risk is heightened by sun exposure, hormonal therapies (oral contraceptives, hormone replacement), pregnancy, and phototoxic drugs. Understanding these determinants is essential for risk stratification and personalized preventive strategies in clinical practice.

Clinical Features

Psoriasis typically presents as well-demarcated erythematous plaques with silvery scaling, predominantly involving the scalp, elbows, knees, and lumbosacral region. Variants include guttate, inverse, pustular, and erythrodermic forms. Disease severity is graded via the Psoriasis Area and Severity Index (PASI) and body surface area involvement. Melasma is characterized by symmetric, hyperpigmented macules and patches on sun-exposed facial areas, notably the malar, centrofacial, and mandibular regions. Both disorders may have significant psychosocial sequelae, necessitating holistic management.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by characteristic morphology and distribution; histopathological confirmation is reserved for atypical cases. Screening for comorbidities and assessment of disease impact (DLQI, PASI) are recommended. Melasma diagnosis relies on clinical examination, Wood's lamp assessment to distinguish epidermal from dermal involvement, and exclusion of mimickers such as post-inflammatory hyperpigmentation, lichen planus pigmentosus, and drug-induced pigmentation.

Treatment & Management

Management of psoriasis and melasma is tailored to disease severity, patient comorbidities, and response to previous therapies. For psoriasis, first-line oral agents include methotrexate, cyclosporine, and acitretin, each with distinct immunomodulatory mechanisms. Apremilast, a phosphodiesterase-4 inhibitor, offers a favorable safety profile, particularly for milder systemic disease. For melasma, oral tranexamic acid has garnered attention for its antifibrinolytic and antiangiogenic properties, while oral antioxidants (e.g., polypodium leucotomos extract, glutathione) are under investigation. Comprehensive management integrates photoprotection, topical agents, and patient education concerning chronicity and relapse prevention.

Recent Advances / Emerging Therapies

The therapeutic landscape for psoriasis has expanded with the advent of targeted oral agents. Janus kinase (JAK) inhibitors, notably tofacitinib and deucravacitinib (a TYK2 inhibitor), have demonstrated efficacy in moderate-to-severe disease, offering oral bioavailability and rapid onset of action. Ongoing trials are evaluating their long-term safety and optimal positioning relative to biologics. For melasma, recent studies support low-dose oral tranexamic acid as a safe and effective adjunct, although relapse upon discontinuation remains a challenge. Investigational oral agents targeting melanogenesis, vascular modulation, and oxidative stress pathways hold promise for refractory melasma and are subjects of ongoing research.

Guideline Recommendations

International guidelines advocate for individualized, stepwise management of psoriasis, reserving oral systemic agents for moderate-to-severe disease or intolerance to topical therapies. Regular monitoring for hepatotoxicity, nephrotoxicity, and hematological adverse effects is essential with traditional immunosuppressants. For melasma, consensus guidelines recommend oral tranexamic acid in selected patients unresponsive to topical therapy, with precautions regarding thromboembolic risk. Shared decision-making, informed consent, and periodic reassessment are integral to optimizing therapeutic outcomes and minimizing complications.

Conclusion

The advent of novel oral therapies marks a significant advancement in the management of psoriasis and melasma, offering expanded options for patients with recalcitrant or extensive disease. While efficacy and safety profiles of emerging agents are encouraging, careful patient selection, monitoring, and adherence to guideline-based recommendations remain paramount. Ongoing research into disease pathogenesis and therapeutic targets is expected to further refine oral treatment strategies, ultimately enhancing patient care and quality of life in dermatology practice.